Auburn University research leads to gene therapy that provides hope for children with deadly disease

奥本大学研究人员发现儿童GM1神经节苷脂病基因疗法

2019-12-04 09:22:23 CISION

本文共1227个字,阅读需4分钟

Auburn University research and the heart-wrenching experience of an Opelika, Alabama, couple are providing hope to children facing the deadly genetic disease, GM1 gangliosidosis. The optimistic outlook is seen in an adorable 10-year-old girl named Jojo, who became the first patient to receive a gene therapy treatment, called AXO-AAV-GM1, during a human clinical trial this summer at the National Institutes of Health in Maryland. Auburn's College of Veterinary Medicine and the University of Massachusetts Medical School developed the treatment that has moved from helping cats with GM1 to hopefully helping children. "Jojo is doing well and has experienced no major complications," said Dr. Doug Martin, professor in the Department of Anatomy, Physiology and Pharmacology in Auburn's veterinary college and the Scott-Ritchey Research Center. "Seeing all of the effort come together to help patients who have no treatment options today gives us great hope." Auburn scientists for several decades have researched treatments to improve and extend the lives of cats affected by GM1. Martin is leading Auburn's effort, which was started by his mentor, Professor Emeritus Henry Baker. To move the treatment toward human medicine, Martin developed a partnership with UMass Medical School researchers Drs. Miguel Sena-Esteves and Heather Gray-Edwards, an Auburn alumna—and they have worked collaboratively for 15 years, combining animal and human medicine studies to cure rare diseases that affect both animals and humans. In December 2018, the gene therapy was licensed to Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies. "This treatment is extremely promising because it has worked well in GM1 mice and cats, and it is delivered by a single IV injection that takes less than an hour," Martin said. "We're hopeful that the treatment makes a real difference for patients and their families. "The NIH is hoping to begin treating three or four more children in the next few months. As the trial progresses and more patients are treated, we'll have a good idea of whether the gene therapy helps children as much as it has helped the animals." The NIH clinical trial is led by Dr. Cynthia Tifft, deputy clinical director at the National Human Genome Research Institute. "GM1 gangliosidosis is a devastating disease in young children, for which there are no currently approved treatment options. The development of a safe and effective gene therapy for these patients would be a welcome advancement in the field of pediatric lysosomal storage disorders affecting the brain," Tifft said. For Auburn graduates Sara and Michael Heatherly of Opelika, whose son Porter was the first known case of GM1 in Alabama and died in 2016, the knowledge of a treatment is one of mixed emotions. "We are excited to know there is hope for the future of children diagnosed with GM1," Michael Heatherly said. "We are thankful for everyone who has dedicated their time, resources and careers to move this treatment forward and to Axovant for bringing all of their work to life and making it a reality for GM1 patients. "We understood early on the research would not help Porter, but we wanted to help spread the word of the research and the progress that was being made." The Heatherlys gave Auburn researchers a reason to hope, and work harder for a cure. To honor the family, which held fundraisers for several years to support the research, the College of Veterinary Medicine's Scott-Ritchey Research Center incorporated Porter's likeness in a creative identity for the center. SOURCE Auburn University Related Links http://www.auburn.edu
奥本大学的研究和阿拉巴马 Opelika 的心痛经历为面临致命基因疾病 GM1神经节苷脂病的儿童提供了希望。 这个乐观的前景出现在一个可爱的10岁女孩 Jojo 身上。 Jojo 今年夏天在马里兰州国立卫生研究院进行人体临床试验,成为第一个接受基因治疗的患者,名为 AXO-AAV-GM1。奥本兽医学院和马萨诸塞大学医学院开发了这种治疗方法,从帮助患有 GM1的猫到希望帮助儿童。 奥本兽医学院的解剖学、生理学和药理学教授道格·马丁博士和斯科特·里奇研究中心说:“乔在做得很好,没有经历过重大并发症。”“看到所有的努力一起来帮助今天没有治疗选择的病人给了我们巨大的希望。” 奥本的科学家已经研究了治疗方法,以改善和延长受 GM1影响的猫的寿命。马丁领导奥本的努力,这是由他的导师,名誉教授亨利贝克。 为了将治疗转向人类医学,马丁与 UMass 医学院的研究人员 Drs 建立了合作关系。Miguel Sena-Esteves 和 Heather Gray-Edwards 是 Auburn 的一名校友,他们合作工作了15年,结合动物和人类医学研究,治疗影响动物和人类的罕见疾病。2018年12月,该基因治疗获得开发创新基因治疗的临床阶段公司 Axovant 基因治疗有限公司的许可。 “这种治疗是非常有希望的,因为它在 GM1小鼠和猫身上效果良好,它是通过一个不到一个小时的静脉注射来完成的,” Martin 说。“我们希望这种治疗能给患者和他们的家人带来真正的改变。 “国立卫生研究院希望在未来几个月里再治疗三四个孩子。随着试验的进展和更多的病人得到治疗,我们将很好地了解基因疗法是否能帮助儿童,就像它对动物的帮助一样。” NIH 临床试验由国家人类基因组研究所副临床主任 CynthiaTifft 博士领导。“ GM1神经节苷脂病是一种破坏性的疾病,在儿童,目前没有批准的治疗方案。在影响大脑的儿童溶酶体储存障碍领域,为这些患者开发安全有效的基因治疗将是一个可喜的进展。 奥本大学( Auburn )毕业生萨拉( Sara )和迈克尔•希瑟利( Michael Heathere )来自 Opelika ,后者的儿子波特( Porter )是阿拉巴马州首例已知的 GM1病例,并于2016年去世。 “我们很高兴知道有希望未来的儿童诊断 GM1,”迈克尔希思利说。“我们感谢所有致力于时间、资源和职业的人,他们将这种治疗方法推向前进,感谢 Axovant 将他们的所有工作带到生活中,使 GM1患者成为现实。 “我们很早就了解到这项研究不会对波特有所帮助,但我们想帮助传播研究的内容和正在取得的进展。” 希瑟利夫妇给奥本的研究人员一个希望的理由,并努力工作的治愈。为了表彰这个多年来一直为支持这项研究而举办募捐活动的家庭,兽医学院的斯科特-里奇研究中心将波特的肖像与该中心的创意结合起来。 奥本大学 相关链接 http://www.auburn.edu

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文